Bolt Biotherapeutics (FRA:6LP0) Moat Score: 2/10 (As of Jul. 02, 2026)


FRA:6LP0 Bolt Biotherapeutics Inc FRA:6LP0
55 GF Score
Price €5.18
GF Value €12.26
! 4 Warning Signs
View Full Analysis

What is Bolt Biotherapeutics Moat Score?

Bolt Biotherapeutics FRA:6LP0 55 Moat Score is 2 as of Jul. 02, 2026. GuruFocus rates FRA:6LP0 with a GF Score™ of 55/100 and a GF Value™ of €12.26. The stock has 4 warning signs investors should review. Among 1,400 Biotechnology companies, Bolt Biotherapeutics ranks better than 58.07% on this metric.

Bolt Biotherapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Bolt Biotherapeutics has No Moat: Bolt Biotherapeutics Inc lacks significant market share, intellectual property, or customer loyalty. The biotech industry is highly competitive, and the company has very weak competitive advantages at this stage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bolt Biotherapeutics might have No Moat - Very weak/transient advantages.

Bolt Biotherapeutics  (FRA:6LP0) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bolt Biotherapeutics Moat Score Related Terms

FRA:6LP0 vs AIM, ERNA, RVPH: Moat Score Comparison

For the Biotechnology subindustry, Bolt Biotherapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bolt Biotherapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's Moat Score falls into.


FRA:6LP0
55GF Score
Bolt Biotherapeutics Inc FRA:6LP0
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Bolt Biotherapeutics (FRA:6LP0) has a Moat Score of 2 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Bolt Biotherapeutics ranks #587 out of 1400 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Bolt Biotherapeutics' Moat Score too high?
Bolt Biotherapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Bolt Biotherapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Bolt Biotherapeutics ranks #587 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bolt Biotherapeutics has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' Moat Score compare to AIM and ERNA?
According to the Biotechnology industry distribution chart, Bolt Biotherapeutics ranks #587 out of 1400 companies for Moat Score. This puts Bolt Biotherapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Bolt Biotherapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bolt Biotherapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bolt Biotherapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Bolt Biotherapeutics (FRA:6LP0) has a current Moat Score of 2. The stock's GF Value™ is €12.26, compared to a current price of €5.18 — trading 57.7% below its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Bolt Biotherapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Bolt Biotherapeutics (FRA:6LP0), the current Moat Score is 2 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bolt Biotherapeutics (FRA:6LP0) Overvalued in 2026?

Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued. The current stock price of €5.18 is trading 57.7% below its estimated GF Value™ of €12.26.

Key valuation signals for FRA:6LP0:

  • Moat Score: 2
  • GF Value™: €12.26 vs. price of €5.18 (57.7% below fair value)
  • GF Score™: 55/100 with 4 warning signs
  • Industry Position: 0% at the Biotechnology median (#587 of 1400)

No single metric tells the full story. See the FRA:6LP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bolt Biotherapeutics Business Description

Other Exchanges BOLT:USA
Address 900 Chesapeake Drive, Redwood City, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
55GF Score

Get the complete analysis for FRA:6LP0

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.18
Price
€12.26
GF Value